Principal Investigator: Dennis Luke Murphy
Dennis Luke Murphy
Section on Clinical Neuropharmacology
Laboratory of Clinical Sciences
Dr. Murphy is Chief of the Laboratory of Clinical Science in the National Institute of Mental Health Intramural Research Program. He received his undergraduate degree from Marquette University, his medical degree (M.D.) and Master of Science (Sc.M.) degrees from the Medical College of Wisconsin and completed his internship and residency programs at the University of Minnesota and Johns Hopkins University. He has received awards for his research, serves on the editorial boards of neuroscience and pharmacology journals and is on the Advisory Boards of Associations and Foundations.
The Laboratory of Clinical Science (LCS) explores the neurobiology of neuropsychiatric disorders using molecular, neurochemical and genetic techniques. Its present focus links studies of transgenic mice with clinical brain disorders using gene-environment interaction models. The serotonin, dopamine and glutamate neurotransmitter systems are among key molecules and these transporters are the primary targets of LCS research. The development and study of the knockout mice in the LCS provides new living tools to discover what systems do in the brain. Drugs that target these transporters include molecules used as SERT and serotonin receptors are the target molecules for the largest numbers of neuropsychiatric drugs used in the world. The 30 plus neurochemical, behavioral and other phenotypic changes discovered in the serotonin knockout mouse are helping to guide the LCS and other laboratories in investigations of the more than 10 variants recently discovered in the human SERT gene. Mice lacking the dopamine transporter and mice lacking or over-expressing the neuronal glutamate transporter are also under intensive study.
miR-15a and miR-16 regulate serotonin transporter expression in human placental and rat brain raphe cells. Moya PR, Wendland JR, Salemme J, Fried RL, Murphy DL. Int J Neuropsychopharmacol. 2012 May 8:1-9. PMID: 22564678.
Human serotonin transporter gene (SLC6A4) variants: their contributions to understanding pharmacogenomic and other functional G×G and G×E differences in health and disease. Murphy DL, Moya PR. Curr Opin Pharmacol. 2011 Feb;11(1):3-10. doi: 10.1016/j.coph.2011.02.008. Epub 2011 Mar 23. PMID: 21439906.
Obsessive-compulsive disorder and its related disorders: a reappraisal of obsessive-compulsive spectrum concepts. Murphy DL, Timpano KR, Wheaton MG, Greenberg BD, Miguel EC. Dialogues Clin Neurosci. 2010;12(2):131-48. PMID: 20623919.
Targeting the murine serotonin transporter: insights into human neurobiology. Murphy DL, Lesch KP. Nat Rev Neurosci. 2008 Feb;9(2):85-96. doi: 10.1038/nrn2284. PMID: 18209729.
A novel, putative gain-of-function haplotype at SLC6A4 associates with obsessive-compulsive disorder. Wendland JR, Moya PR, Kruse MR, Ren-Patterson RF, Jensen CL, Timpano KR, Murphy DL. Hum Mol Genet. 2008 Mar 1;17(5):717-23. Epub 2007 Nov 30. PMID: 18055562.
Magnuson Clinical Center, Room 3D41, MSC 1264
Bethesda, MD 20814
Phone: +1 301 496 2757
Fax: +1 301 402 0188